Baxter is investing in Belgium
Pharmaceutical company Baxter is investing EUR 50 million in its production site in Lessines. This money will be used to build a new unit of 4,500 m² and create approximately 50 extra jobs. As of 2014, a new medicine named Glassia will be produced for the American market.
Baxter manufactures pharmaceutical products to treat haemophilia, immunity disorders, cancer, infectious diseases, renal disorders and traumas. Blood plasma-based medicines and home dialysis-based medication are produced in Lessines. There is also a European distribution centre at this site.
Belgium was the first country outside the United States in which the American company has invested. Over the past 50 years, the company has expanded its base in the province of Hainaut to a complex of approximately 75,000 m², which employs over 2,200 people.